Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) FCF Margin (2016 - 2025)

Historic FCF Margin for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to 25.73%.

  • Haemonetics' FCF Margin rose 156200.0% to 25.73% in Q4 2025 from the same period last year, while for Dec 2025 it was 23.37%, marking a year-over-year increase of 161700.0%. This contributed to the annual value of 10.47% for FY2025, which is 5000.0% down from last year.
  • Per Haemonetics' latest filing, its FCF Margin stood at 25.73% for Q4 2025, which was up 156200.0% from 32.48% recorded in Q3 2025.
  • In the past 5 years, Haemonetics' FCF Margin registered a high of 32.48% during Q3 2025, and its lowest value of 9.84% during Q2 2024.
  • Over the past 5 years, Haemonetics' median FCF Margin value was 10.75% (recorded in 2024), while the average stood at 10.01%.
  • In the last 5 years, Haemonetics' FCF Margin tumbled by -201000bps in 2023 and then surged by 211400bps in 2024.
  • Over the past 5 years, Haemonetics' FCF Margin (Quarter) stood at 9.44% in 2021, then skyrocketed by 65bps to 15.58% in 2022, then tumbled by -129bps to 4.52% in 2023, then skyrocketed by 324bps to 10.1% in 2024, then surged by 155bps to 25.73% in 2025.
  • Its last three reported values are 25.73% in Q4 2025, 32.48% for Q3 2025, and 4.24% during Q2 2025.